Alzheimer’s is a massive market and really doesn’t have a great treatment. I don’t remember which BP it was, but a large BP discontinued a Alzheimer’s trial a few years ago, a phase 2b/3, based on an intern analysis is that showed poor results. If I remember correctly, they’re market cap went down $10-20 billion as a result of the bad results. That should give you an idea of how much a good Alzheimer’s treatment is worth.

But I’m not convinced of the Alzheimer’s indication at this point. CYDY hasn’t quite explained what results or preclinical study indicated leronlimab might work for the disease. There are preclinical mice for Alzheimer’s testing, so maybe CYDY will conduct one and publish the results.